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Young women with a prosthetic heat? valve often wish to bear children (1). Pregnancy in such patients is associated with increased risk due to various causes, including increased blood volume and hemodynamic burden, hypercoagulable state of pregnancy leading to increased incidence of thromboemboiic events and the exposure of the fetus to cardiovascular drugs required to treat maternal disease. Oral anticoaguian! agents have been considered contraindicated in pregnancy because of theii reported teratogenic effect and resulting abnormalities. In contrast, heparin does not cross the placenta because of its large molecule, and recent experience (2) in a large number of patients who received heparin during pregnancy has shown a normal fetal and neonatal outcome without an increase in maternal bleeding complications. Although subclinical reduction in bone density is a potential consequence of long-term heparin therapy in pregnancy, it is usually reversible, and the risk of symptomatic bone fracture is small (3). For ah these reasons, it is not surprising that the use of heparin has been preferred during pregnancy in patients requiring anticoagulation therapy (4) . In thii issue of the Journal, Sabsaar et al. (5) describe their prospective experience with 40 pregnancies in 37 women with prosthetic heart valves who received subcutaneous heparin from the 6th week to the end of the 12th week and for the last 2 weeks of gestation. The authors report fatal valve thrombosii during heparin therapy in two cases and conclude that subcutaneous heparin is not effective in the prevention of mechanical vaIve thrombosis during pregnancy. On the basis of their 8ndings, the authors recommend the use of oral anticoagtdation throughout pregnancy with a change to heparin only during the last 2 weeks of gestation. These group of investigators have had a long-standing interest in the management of pregnant patients with prosthetic heart valves. Their previous publications (6,7) had a substantial impact on the care of such patiems, and theii present report is likely to have a Similar e&et. For this reason, the results of the study should be analyzed very carefuhy and in content of other avaihtble data. (8) reported the occurrence of valve thrombosis in patients with older generation mechanical prosthesis, such as Starr-Edwards and Bjork-Shiley valves, and in all cases the prosthetic valve involved was in the mitral position. Should the recommendations to use Coumadin during most of the pregnancy, including the first trimester, be extended to newer, less thrombogenic prosthetic heart valves and to valves in the aortic position? The answer to these questions is difficult, mairdy for tack of sufficient information. However, Sareli et al. (9) reported a low incidence of thromboembohsm despite inadequate anticoagulation during 50 pregnancies in women with 60 mechanical valves. The majority of these patients bad newer generation mechanical prostheses (Medtronic-Hall and St. Jude Medical) and were treated with Coumadin during the first two trimesters of gestatiou and heparin during the last trimester. Measured prothrombin ratio was found to be within the therapeutic range in only 39% of cases. These data may indicate a lower likelihood of thromboembolii events during pregnancy in patients with newer generation prosthetic heart valves.
A reported high rate of valve thrombosis during heparin therapy may be due to inadequate heparin dose or lack of stringent monitoring of activated partial thromboplastin time (aPIT). Although the authors state that vaIve thrombosis occurred despite adequate heparin dosing, data are not pmvided. In addition, the minimal target aPTI ratio of 1.5 used by these investigators has recently been suggested to be too low (3) . Similarly, no information regarding adequacy of heparin dose and aPTI monitoring in cases with valve thrombosis is provided by Sbarouni et al. (9) . In addition, anecdotal information clearly demonstrates that valve thrombosis during pregnancy is not unique to heparin and can also occur in patients receiving Coumadin theray, especiahy when adequate monitoring is not available (lti-12).
Sbarouni et al. (9) repoited no embryopathies in a group of 46 women who were treated with warfarin during the Iirst gestational trimester and state that embryopatby is rare when a dose of warfarin is well controUed. In cona can&I evahmtion in two other studies resulted in diignosing signs of embryopothy in as many as 29% (6) and 67% (13) of newborns, respectkrety. The authors (5) indicate that many cItiIdren with coumadin embryopathy have only minor abnormalities. How-ever, this can hardly be used as reassurance because the severity of the syndrome in an individual case is unpredictable, and many women are more likely to accept a possible increased risk to themselves before accepting the risk of "only" minor abnormalities in their children (1). In recent weeks, we consulted on two pregnant patients with prosthetic valves. The first had a Bjiirk-Shiley valve in the mitral position due to an episode of bacterial endocarditis and the second a St. Jude valve in the tricuspid position due to Ebsteio's anomaly. The latter patient developed valve thrombosis during gestation and was treated successfully with urokinase. Both patients and their physicians were informed of the reports by Sahxar et al. (7) and Sbarouni et al. (8) , and both elected to be treated with heparin. This experience suggests the need for an alternative drug regimen for high risk patients xho may not wish to receive Coumadin during the tirst gestational trimester.
The use of a bioprosthetic valve can obviate the need for prolonged anticoagulation and, therefore, may seem a more appropriate choice in a woman with no other reason for anticoagulation during the childbearing age. However, several reports (5,8) (14) demonstrated pregnancy-related stmctural deterioration reqiring valve reoperation. Although the risk of mortahty associated with a valve re-replacement has not been systematically evaluated in women of childbearing age, it has been reported to be 8.7% by one group (14) .
Summary and recommemIatIans. Anticoagulation in a patient with a mechanical heart valve during pregnancy presents a double jeopardy with risk both to the mother and the fetus. The study by Salazar et al. (5) and a recently published survey (8) have reported increased incidence of vaIve thrombosis in women treated with subcutaneous beparin and led to the recommendations to use Coumadm throughout pregnancy. However, exposure of the fetus to Coumadii may result in severe fetal consequences due to teratogenic effects and intracranial bleeding (4) . The data presented and other available in Jrmation are limited by either a small number of patients or by a retrospective design and possible selective and incomplete reporting. Any recommendations at the present time, therefore, cannot be detinitive, are temporary and need to be further validated. Women with older generation prosthetic valves in the mitral position should be informed of the potential risk of valve thrombosis with heparin therapy and should consider the use of Gxmmdin thmqhout gestation with heparin before deEvery. In high risk women who choose not to take Coumadin during C.te first trimester, in-hospital wntinuous intravenous heparin treatmen& at least between weeks 6 and 12, seems just&d. In patients with older generationprostheticvalvesbutintheaorticpn6itionandthosewith newer generation heart vahe in any positioih subattt hepminshouldbeusedduringthe&sttrimesterandintheM partofgestation.ThedoseofheparinshouIdbeadjustedto proIongthemidintervalaIlT~tothreethnesa?ntNi value, and adequacy of anticoagulation should be monitored at least once every 1 to 2 weeks. Administration of heparin by subcutaneou< infusion with a programmable pump has been demonstrate* to achieve mom even control with fewer complications than intermittent subcutaneous injection technique (1.5) and should be considered in patients with prosthetic valves.
Low molecular weight heparin may be an attractive drug for use during pregnancy. Similar to standard unfractionated heparin, it does not cross the placenta, and at the same time, it may provide additional benefits, including reduced incide..ce of heparin-induced thrombocytopenia, osteoporosis and bleeding complications, and no blood test is required to monitor its safety (16) . The drug has been used effectively and safely to treat deep vein thrombosis during pregnancy, but data in patients with a prosthetic valve are not avai!able. Because a small dose of aspirin is safe during pregnancy (3), it may be used in addition to anticoagulation to maxim& the antithrombotic effect The concomitant use of diidamole is not recommended because of high fetal loss demonstrated in one study (9) .
Premature labor frequently occurs in women with prosthetic heart vatvcs. In the study by Sa'azar et al. (5) 36% of the neonates were born before the 37th week of gestation, and one neonate died of cerebral hemorrhage that ccctnred during labor due to Cixrmadin treatment. These data suggest the need to substitute Coumadin with a therapeutic dose of heparin no later than 35 or 36 weeks of gestation to avoid the onset of labor during Coumadin therapy. In patients with older generation mitral prosthesis in the hospital iatravenous heparin therapy until term may be advisable to minimize the risk of vaIvethmmhoGiCesareansectionshouIdbeusedasamode of delivery in patients who go into labor during treatment with oral anthagtdation to prevent fetal cerebral hemorrhage during vaginal delivery.
The present study by Salazar et al. (5) is another attempt to resolve the dilhcult issue of anticoag&tion in patients with a mecha&alheartvalveduringpregnaq Howtxer, this attempt fails to provide clear guidelines for the treatment of nrh patients. In addition, the recommendations by the authors for the use of Coumadin, a drug dedared by its manufacturer contraindicated during pregnanq, also present a double jeep ardyforphyGc&swhomaybebIamedforusingthedrugor for not using it during pregnaq. A strong plea should therefore be made for a large, prospective. randomii and well controlled study to evaluate the eihcacy and safety of various antiatqulation regimens in women with pros&tic heart valves during pregnancy.
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